Torsade de pointes induced by cisapride/clarithromycin interaction

Annals of Pharmacotherapy

Volumn 33, Issue 1, 1999, Pages 22-26

  Piquette, Rosemary K ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Cisapride; Clarithromycin; Cytochrome P450 enzymes; Torsade de pointes

Indexed keywords

ANTIHISTAMINIC AGENT; CISAPRIDE; CLARITHROMYCIN; COTRIMOXAZOLE; CYTOCHROME P450; IMIDAZOLE DERIVATIVE; MACROLIDE; MAGNESIUM; POTASSIUM;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; DRUG METABOLISM; ELECTROLYTE BALANCE; FEMALE; HUMAN; PNEUMONIA; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR; TORSADE DES POINTES;

AGED; ANTI-BACTERIAL AGENTS; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MIXED FUNCTION OXYGENASES; NAUSEA; PNEUMONIA; TORSADES DE POINTES;

EID: 0032904146     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18107     Document Type: Article

References (33)

1. Napolitano C, Priori SG, Schwartz PJ. Torsade de pointes mechanism and management. Drugs 1994;47:51-65.
2. Faber TS, Zehender M, Just H. Drug-induced torsade de pointes: incidence, management and prevention. Drug Saf 1994;11:463-76.
3. Raehl CL, Patel AK, LeRoy M. Drug-induced torsade de pointes. Clin Pharm 1985;4:675-90.
4. Gilter B, Berger LS, Buffa SD. Torsade de pointes induced by erythromycin. Chest 1994;105:368-72.
5. Wilt JL, Minnema AM, Johnson RF, Rosenblum AM. Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 1993;119:391-4.
6. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996;94: 2535-41.
7. Ciummo PE, Katz NL. Interactions and drug-metabolizing enzymes. Am Pharm 1995;NS35:41-51.
8. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.
9. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6.
10. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction. JAMA 1993;269:1513-8.
11. von Rosenstiel N-A, Adam D. Macrolide antibacterials: drug interactions of clinical significance. Drug Saf 1995;13:105-22.
12. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995;29:906-17.
13. Tinel M, Descatoire V, Larrey D, Loeper J, Labbe G, Letteron P, et al. Effects of clarithromycin on cytochrome P-450. Comparison with other macrolides. J Pharmacol Exp Ther 1989;250:746-51.
14. Tatum WD, Gonzales MA. Carbamazepine toxicity in an epileptic induced by clarithromycin. Hosp Pharm 1994;29(1):45-6.
15. Sketris IS, Wright MR, West ML. Possible role of the intestinal P-450 enzyme system in a cyclosporine-clarithromycin interaction. Pharmacotherapy 1996;16:301-5.
16. Gascon MP, Dayer P. Comparative effects of macrolide antibiotics on liver monoxygenases (abstract). Clin Pharmacol Ther 1991;49:158.
17. Honig PK, Wortham DC, Zamani K, Cantilena LR. Comparison of the effects of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters. Drug Invest 1994;7:148-54.
18. Lai D, Brown G, MacDonald I. Clarithromycin-induced prolonged QT syndrome. Can J Hosp Pharm 1996;49:33-5.
19. Barone JA, Jessen LM, Colaizzi JL, Bierman RH. Cisapride: a gastrointestinal prokinetic drug. Ann Pharmacother 1994;28:488-500.
20. Product information. Cisapride (Prepulsid). North York, Ontario: Janssen Pharmaceutica, August 29, 1989 (revised April 14, 1997).
21. Olsson S, Edwards IR. Tachycardia during cisapride treatment. BMJ 1992;305:748-9.
22. Inman W, Kubota K. Tachycardia during cisapride treatment (letter). BMJ 1992;305:1019.
23. Bran S, Murray WA, Hirsch IB, Palmer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-8.
24. Canadian Adverse Drug Reaction Newsletter 1996;6(3).
25. Australian Adverse Drug Reactions Bulletin 1996;15(3).
26. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia (letter). N Engl J Med 1996;335:290-1.
27. Sekkarie MA. Torsade de pointes in two chronic renal failure patients treated with cisapride and clarithromycin. Am J Kidney Dis 1997;30: 437-9.
28. Humphrey PPA, Bunce KT. Tachycardia during cisapride treatment (letter). BMJ 1992;304:1019.
29. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? Pharmacol Exper Ther 1997;282:220-7.
30. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsade de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol 1987;50:376-7.
31. Darpo B, Walfridsson H, Aunes M, Bergfeldt L, Edvardsson N, Linde C, et al. Incidence of sudden death after radiofrequency ablation of the atrioventricular junction for atrial fibrillation. Am J Cardiol 1997;80:1174-7.
32. De Vane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994;97(suppl 6A):13-23S.
33. Swims MP. Potential terfenadine-fluoxetine interaction (letter). Ann Pharmacother 1993;27:1404-5.